[HTML][HTML] Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
…, AM Vannucchi, M Ruggeri, E Elli, C Micò… - …, 2008 - haematologica.org
Background Prior thrombosis is a well-established risk factor for re-thrombosis in polycythemia
vera and essential thrombocythemia but scarce data are available on the rate of re-…
vera and essential thrombocythemia but scarce data are available on the rate of re-…
[HTML][HTML] Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients
…, F Pavan, F Masciocchi, A Algarotti, C Micò… - Biology of blood and …, 2014 - Elsevier
This phase I multicenter study was aimed at assessing the feasibility and safety of
intravenous administration of third party bone marrow–derived mesenchymal stromal cells (MSC) …
intravenous administration of third party bone marrow–derived mesenchymal stromal cells (MSC) …
Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support
BackgroundSevere COVID-19 is characterised by interstitial pneumonia and hyperinflammation,
with elevated levels of pro-inflammatory cytokines, such as IL-6. Effective treatments are …
with elevated levels of pro-inflammatory cytokines, such as IL-6. Effective treatments are …
[HTML][HTML] Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute …
…, E Oldani, A Grassi, T Intermesoli, C Micò… - …, 2007 - haematologica.org
Background and Objectives The molecular analysis of minimal residual disease (MRD) may
provide informaton on the risk of recurrence in patients with acute lymphoblastic leukemia (…
provide informaton on the risk of recurrence in patients with acute lymphoblastic leukemia (…
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey
…, G Finazzi, F Delaini, C Mico… - Blood, The Journal …, 2008 - ashpublications.org
A multicenter retrospective analysis was performed to estimate the frequency of thrombosis
and hemorrhage after surgical procedures in patients with polycythemia vera (PV) and …
and hemorrhage after surgical procedures in patients with polycythemia vera (PV) and …
IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study
… Caterina Micò reports travel support from Medac, outside the submitted work. Diego
Ripamonti reports personal fees from Gilead, Janssen and ViiV, outside the submitted work. …
Ripamonti reports personal fees from Gilead, Janssen and ViiV, outside the submitted work. …
[HTML][HTML] Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
Severe coronavirus disease 2019 (COVID-19) is characterized by interstitial pneumonia/acute
respiratory distress syndrome and hyperinflammation, with elevated levels of …
respiratory distress syndrome and hyperinflammation, with elevated levels of …
[HTML][HTML] Phase II study of sequential infusion of donor lymphocyte infusion and cytokine-induced killer cells for patients relapsed after allogeneic hematopoietic stem …
…, A Algarotti, E Gotti, R Valgardsdottir, C Micò… - Biology of Blood and …, 2017 - Elsevier
Seventy-four patients who relapsed after allogeneic stem cell transplantation were enrolled
in a phase IIA study and treated with the sequential infusion of donor lymphocyte infusion (…
in a phase IIA study and treated with the sequential infusion of donor lymphocyte infusion (…
[HTML][HTML] Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation
…, G Borleri, C Capelli, A Algarotti, C Micò… - Biology of Blood and …, 2010 - Elsevier
Five patients with aggressive acute leukemias who had relapsed after cord blood transplantation
were treated with cord blood derived cytokine-induced killer (CIK) cells. These were …
were treated with cord blood derived cytokine-induced killer (CIK) cells. These were …
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
…, E Rossi, AM Vannucchi, M Ruggeri, E Elli, C Micò… - Annals of …, 2010 - Springer
Evidence suggests that the JAK2 V617F mutation is associated with an increased risk of first
thrombosis in patients with essential thrombocythemia (ET). Whether this mutation is also a …
thrombosis in patients with essential thrombocythemia (ET). Whether this mutation is also a …